Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. It also develops CLR 121125, an iodine-125 Auger-emitting radioconjugate program; and CLR 225, an actinium-225 based radioconjugate program. The company has collaborative with Orano Med to develop alpha emitter lead-212 conjugated to phospholipid ether series; and LegoChem Bio. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.…
Cellectar Biosciences, Inc. Q3 2026 Earnings Call Summary
Cellectar Biosciences (NASDAQ: CLRB) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 11 employees.
The shares were at 0.7970 USD on 20 November 2026, down 76.5% over 52 weeks. Its 52-week range is 0.7596 USD to 4.700 USD: the price is 83.0% below the high and 4.9% above the low.
Its market capitalisation is 8.00M USD.
Cellectar Biosciences reports return on equity of -255.2% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 23.05M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. The next earnings report is expected on 3 March 2027.